Figure 1 from Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells

Identification of an immune-related PARP7i and AHRa response biomarker in cancer cell lines. A, Overview of the workflow to develop an immune-related PARP7i and AHRa response biomarker. RNA-seq data from DepMap were used to identify DEGs between cell lines showing synergistic growth inhibition by PARP7i and AHRa combination treatment and those showing no synergy. The subset of immune-related DEGs (FC > 8; P < 0.05) was used to define an mRNA-based biomarker to predict PARP7i and AHRa combination response. B, Venn diagram showing the intersection of DEGs in the training set and two lists of immune genes, ImmPort and Immunome. C, Scatter plot showing biomarker scores of synergistic and nonsynergistic cell lines in the training set. Biomarker scores were calculated as the average mRNA expression level of CCL22 and TNFSF10. A dashed line indicates the cutoff used to classify synergistic and nonsynergistic groups. A Student t test was used to calculate statistical significance. D, ROC curve showing the performance of the two-gene classifier in distinguishing synergistic responses to PARP7i and AHRa in the training set of cell lines. The dashed diagonal line marks the performance of a random signature. The asterisk marks sensitivity and specificity selected to calculate the cutoff score to classify synergy vs. non-synergy. AUC, sensitivity, and specificity are indicated.